Weil's Pharmaceuticals & Biotechnology
practice is comprised of an impressive blend of legal services tailored to the needs of innovator companies.
The firm’s Patent Litigation practice group features excellent bench strength, sound judgment, and a strong command of multiple treatment areas, technologies, and jurisdictions. We have deep experience with multiple classes of pharmaceutical and biologic therapies and all technologies relating to drug research, discovery, and delivery. In addition, our group has accumulated extensive trial experience in multiple key U.S. jurisdictions – including “plaintiff-friendly” districts that are popular venues for those who seek to file nuisance law suits against industry innovators – as well as before the International Trade Commission. This strength in intellectual property is buttressed by an equally impressive array of litigation skills in commercial litigation, antitrust, and product liability, providing innovator drug companies with the full range of litigation and regulatory expertise needed to address its strategic challenges. Our Corporate Department also has a long-time association with select clients in the pharmaceuticals and biotechnology industries, handling corporate acquisitions and divestitures, the raising of capital through private equity deals and other financing methods, and advising established companies as they structure strategic alliances.
Recent representative transactions and litigations include:
Sanofi in its decision to combine Merial with Intervet/Schering-Plough, Merck & Co.’s animal health business. This joint venture follows Sanofi’s $4 billion acquisition of Merck’s 50 percent interest in Merial Limited in 2009;
Merck in a successful patent infringement suit which upheld Merck’s patent on SINGULAIR® (montelukast sodium), one of the world’s leading prescribed branded respiratory medications;
Sanofi in its approximately $1.9 billion acquisition of U.S. healthcare company Chattem Inc.;
Bioton SA in a groundbreaking supply and distribution agreement between Bioton and its subsidiary SciGen Ltd. and Bayer Healthcare Company Limited. The agreement allows Bayer to acquire the right to market and distribute insulin produced by Bioton and SciGen Ltd.;
Genentech in connection with patent rights to DNA sequences encoding potentially key cancer therapeutics. Plaintiff Human Genome Sciences (HGS), one of the companies involved in sequencing the human genome, brought suit claiming that it had invented the relevant DNA sequences first;
Medicis Pharmaceutical Corporation in its successful defense in patent law suit against where plaintiff IMPAX Laboratories sought a declaratory judgment that Medicis’s Solodyn® patent was invalid and not infringed.